20151103 TG1050 FINAL VERSION US
Category: dates
Transgene Reports Third Quarter 2015 Financial Results
20151021 PR US Q3 2015 FINAL
Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
23092015 PR ladenburg conf_EN
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
20150910 – PR 2015 H1 results final
TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.
Elisabeth Quoix, et al. 16th World Conference on Lung Cancer. September 2015, Denver, Colorado Download the poster here Poster Presentation
Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
20150908 PR TG4010 IASLC revised – BIS
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
19 August 2015_PR_IASLC curtain raiser_ENG
Transgene plans restructuring to focus on research and development
20150629 PR 29 juin fin
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
20150601 PR TG4010 TIME results_ASCO 2015_FINAL